Wellington Management Group LLP Has $36.54 Million Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Wellington Management Group LLP decreased its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 1.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 786,312 shares of the company's stock after selling 11,425 shares during the period. Wellington Management Group LLP owned 1.32% of Twist Bioscience worth $36,540,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of TWST. Barclays PLC lifted its holdings in shares of Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after buying an additional 104,420 shares during the last quarter. Blue Trust Inc. grew its position in Twist Bioscience by 19.9% in the fourth quarter. Blue Trust Inc. now owns 4,567 shares of the company's stock worth $206,000 after acquiring an additional 757 shares in the last quarter. KBC Group NV grew its position in Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after acquiring an additional 1,226 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Twist Bioscience by 11.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,586 shares of the company's stock worth $585,000 after purchasing an additional 1,318 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock valued at $31,636,000 after purchasing an additional 302,884 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TWST. JPMorgan Chase & Co. decreased their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Robert W. Baird decreased their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group cut their price objective on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Barclays decreased their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Finally, Guggenheim reiterated a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $50.40.

Insider Activity

In other Twist Bioscience news, CEO Emily M. Leproust sold 2,402 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $98,265.82. Following the completion of the transaction, the chief executive officer now owns 662,692 shares of the company's stock, valued at $27,110,729.72. This represents a 0.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Adam Laponis sold 936 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $27,846.00. Following the sale, the chief financial officer now owns 106,018 shares in the company, valued at approximately $3,154,035.50. This represents a 0.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,850 shares of company stock valued at $974,764. Insiders own 3.01% of the company's stock.

Twist Bioscience Stock Performance

Shares of TWST stock traded up $1.77 during trading hours on Monday, reaching $31.07. 1,909,265 shares of the company's stock were exchanged, compared to its average volume of 984,619. Twist Bioscience Co. has a fifty-two week low of $27.12 and a fifty-two week high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.86 billion, a P/E ratio of -9.19 and a beta of 2.54. The business has a fifty day moving average price of $35.28 and a 200-day moving average price of $42.29.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The company had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.